Popular on TelAve
- OddsTrader Asks: What Are the Chances Your Team Makes the NFL Playoffs? - 868
- Zoiko Orbit Launches: Seamless Global Travel Connectivity in 200+ Countries, Including Africa - 669
- EMBER™, the Only Standardized System Linking Workforce Identity to Growth, Appoints Global Brand Visionary Bret Sanford-Chung to Board of Directors - 452
- Iterators Named Preferred Accessibility Testing Vendor by MIT - 426
- Sober.Buzz Adds Second Podcast, "Spreading the Good BUZZ" Guest List Grows, Numbers Continue Growing Globally, All While Josh and Heidi Tied the Knot - 424
- ScaleFibre Launches SmartRIBBON™ High-Density Optical Fibre Cables - 364
- How AI Exposed Major Flaws in the Foundation & Structure of Technology, Hardware & the Internet & Phinge's® Patented Netverse®, App-less Solution - 264
- Heritage at South Brunswick Announces Two New Building Releases In Townhome Collection - 249
- Autohaus of Boston Launches Luxury Ferrari Winter Storage Experience - 244
- SQUARESIGNS Featured in Inc.5000 List Again - 228
Similar on TelAve
- New Leadership and Renovations Usher in Next Chapter for Sunrise Manor
- Who Will Win the 2025 WNBA Finals? OddsTrader Shares Live Betting Odds and Projections
- Dental Surgical Center Accepts Sedation Patients with Medicaid for MD, WV, PA and DC
- Sloan's Lake Dental Launches New Website to Enhance Patient Experience and Access to Modern Dental Care
- Vesica Health Receives AUA Guideline Inclusion
- Steward's Plumbing Sponsors the 2025 Samson Challenge, Bringing Community, Fitness, and Fun Together in Albuquerque
- CCHR: Involuntary Commitment Is Eugenics Repackaged as "Mental Health Care"
- Physician-Turned-Patient Launches Advocacy Campaign to Spotlight Disability Insurance Barriers
- Your Body Isn't Broken—It's Out of Balance: The New Book Revealing the Blueprint to Restore Hormone Balance, Sleep, Gut & Metabolic Health
- Youth Take the Lead: Kopp Foundation for Diabetes Hosts "By Youth, For Youth, With T1D" Gala on October 8 at Blue Bell Country Club
Dr. Jeff Gelblum Provides Alzheimer's Treatment to Patients in the US and Abroad
TelAve News/10835940
AVENTURA, Fla. - TelAve -- Dr. Jeff Gelblum, Neurologist at First Choice Neurology, has brought together clinical, imaging, and laboratory capabilities to provide rapid diagnosis and treatment to individuals suffering from Alzheimer's disease.
The patient journey of Alzheimer's evaluation and management involves a clinical assessment to determine the level of cognitive impairment, and imaging studies of the brain, MRI, and PET scans to identify the presence of brain amyloid plaques. Also included are laboratory capabilities to inform the tolerability of the new anti-Alzheimer medication, and an experienced infusion team capable of providing the new class of FDA-approved medication in a comfortable setting.
Dr. Gelblum's highly integrated program will eliminate the long delays and fragmented care that typically plague patients seeking Alzheimer's treatment.
He observes, "that the new class of disease-modifying treatments are only approved in mild Alzheimer's which offers only a short window of opportunity to treat. In the US and abroad, it can often take up to a year to get a neurology appointment, and by that point, the patient may have progressed to a point where they might no longer respond to treatment."
More on TelAve News
Dr. Gelblum's program eliminates the delay and provides a quick and comprehensive work-up in the Aventura medical district, just north of Miami, Florida.
Dr. Gelblum boasts that "within 48 hours we can diagnose and begin infusion therapy. This means that the patient can check in to our on-campus hotel on a Tuesday evening, undergo evaluation in our clinic Wednesday morning, receive diagnostic testing Wednesday and Thursday, and then obtain their infusion treatment on Friday."
For those patients who reside out of town, his infusion center can dispense medication to-go for follow-up infusion treatments in their hometown medical facility. This is ideal for out-of-town patients who may not have easy access to a neurologist. He can then follow the patient remotely via telehealth.
His Aventura clinic is easily accessible via Miami or Fort Lauderdale international airports.
Dr. Gelblum has a global patient population who has discovered the ease of access and convenience of care provided by this program. He has patients from the UK, Spain, France, Israel, Russia, South Korea, Central and South America, and the Caribbean. They are diagnosed in his Aventura clinic and then followed up remotely via Skype, WhatsApp, FaceTime, or any manner of live audiovisual interface.
More on TelAve News
Dr. Gelblum observes, "that in this day and age of disease-modifying therapy and instantaneous telecommunications, it is unacceptable for medically necessary neurological care and treatment to be delayed."
He looks forward to welcoming Alzheimer patients from all over to his Aventura, Florida clinic.
About Jeffrey Gelblum, MD, FAAN
Dr. Jeff Gelblum is a neurologist with First Choice Neurology located in Aventura, Florida. He is considered a global thought leader in the neurologic treatment of Alzheimer's, dementia, seizure disorders, Parkinson's, diabetic and peripheral nerve disorder, Familial Amyloid Polyneuropathy, Covid Long-Hauler, trauma, and chronic pain, and has hosted educational symposia in the U.S. and overseas. To learn more about Dr. Gelblum, visit https://www.fcneurology.net/business-directory/788/jeffrey-gelblum-md/
The patient journey of Alzheimer's evaluation and management involves a clinical assessment to determine the level of cognitive impairment, and imaging studies of the brain, MRI, and PET scans to identify the presence of brain amyloid plaques. Also included are laboratory capabilities to inform the tolerability of the new anti-Alzheimer medication, and an experienced infusion team capable of providing the new class of FDA-approved medication in a comfortable setting.
Dr. Gelblum's highly integrated program will eliminate the long delays and fragmented care that typically plague patients seeking Alzheimer's treatment.
He observes, "that the new class of disease-modifying treatments are only approved in mild Alzheimer's which offers only a short window of opportunity to treat. In the US and abroad, it can often take up to a year to get a neurology appointment, and by that point, the patient may have progressed to a point where they might no longer respond to treatment."
More on TelAve News
- 3E Launches First AI Agent Designed to Respond with Empathy for College Recruitment
- Security Alert: TZNXG Warns Investors About "Fund Recovery" Scams
- Assent Unveils Extended Producer Responsibility Packaging Solution to Simplify Compliance with Expanding Packaging Laws
- KatalisCoin: "Too Secure" for Bad Actors - Platform Embraces "Excessive Compliance" Criticism
- Keyanb Exchange Implements Enhanced Security Protocols Amid Industry-Wide Trust Challenges
Dr. Gelblum's program eliminates the delay and provides a quick and comprehensive work-up in the Aventura medical district, just north of Miami, Florida.
Dr. Gelblum boasts that "within 48 hours we can diagnose and begin infusion therapy. This means that the patient can check in to our on-campus hotel on a Tuesday evening, undergo evaluation in our clinic Wednesday morning, receive diagnostic testing Wednesday and Thursday, and then obtain their infusion treatment on Friday."
For those patients who reside out of town, his infusion center can dispense medication to-go for follow-up infusion treatments in their hometown medical facility. This is ideal for out-of-town patients who may not have easy access to a neurologist. He can then follow the patient remotely via telehealth.
His Aventura clinic is easily accessible via Miami or Fort Lauderdale international airports.
Dr. Gelblum has a global patient population who has discovered the ease of access and convenience of care provided by this program. He has patients from the UK, Spain, France, Israel, Russia, South Korea, Central and South America, and the Caribbean. They are diagnosed in his Aventura clinic and then followed up remotely via Skype, WhatsApp, FaceTime, or any manner of live audiovisual interface.
More on TelAve News
- TSWHZC Platform Combines Automated Portfolio Management with Proof of Reserves for Brazil Market Entry
- AureaVault Positions Digital Asset Infrastructure for Shifting Monetary Policy Environment
- JQRBT Unveils High-Speed Trading Infrastructure Designed for Growing Institutional Crypto Market
- New Leadership and Renovations Usher in Next Chapter for Sunrise Manor
- Who Will Win the 2025 WNBA Finals? OddsTrader Shares Live Betting Odds and Projections
Dr. Gelblum observes, "that in this day and age of disease-modifying therapy and instantaneous telecommunications, it is unacceptable for medically necessary neurological care and treatment to be delayed."
He looks forward to welcoming Alzheimer patients from all over to his Aventura, Florida clinic.
About Jeffrey Gelblum, MD, FAAN
Dr. Jeff Gelblum is a neurologist with First Choice Neurology located in Aventura, Florida. He is considered a global thought leader in the neurologic treatment of Alzheimer's, dementia, seizure disorders, Parkinson's, diabetic and peripheral nerve disorder, Familial Amyloid Polyneuropathy, Covid Long-Hauler, trauma, and chronic pain, and has hosted educational symposia in the U.S. and overseas. To learn more about Dr. Gelblum, visit https://www.fcneurology.net/business-directory/788/jeffrey-gelblum-md/
Source: First Choice Neurology
0 Comments
Latest on TelAve News
- Work 365 Launches PV 3.0: The Keystone Power App for Microsoft CSPs
- Local consultant shows small businesses how to turn red tape into real money
- Tour Napa Like a Local: Vines of Napa Valley Wine Passport AKA Vine Pass Unlocks Hidden Gems
- Dental Surgical Center Accepts Sedation Patients with Medicaid for MD, WV, PA and DC
- Sloan's Lake Dental Launches New Website to Enhance Patient Experience and Access to Modern Dental Care
- Only 3 Weeks Left till the Start of the OpenSSL Conference 2025
- ENTOUCH Completes $50 million Funding Round
- Teaming Agreement with Emtel Energy USA to Advance Thin-Film PV Energy Storage Capabilities; NASA agreements for Solar Space Tech; Ascent Solar $ASTI
- Nebuvex Acknowledges Platform "Too Secure" for Anonymous Traders; Institutional Investors Disagree
- From Tokyo to Berlin: FreeTo.Chat Unites Cultures with the World's First Confession VRX — EmojiStream™
- AZETHIO Launches Multi-Million Dollar User Protection Initiative Following Unprecedented Platform Growth
- Matecrypt Observes South American Cryptocurrency Adoption Surge Amid Economic Shifts
- Assent Uncovers Over 695 Unique PFAS Across Global Supply Chains as Regulations Increase
- Cryptocurrency Quarterly Trading Volume Surpasses $15 Trillion Record High as BrazilNex Acknowledges Industry 'Growing Pains' Amid Market Speculation
- AHRFD Initiates Legal Proceedings Against Anwalt.de for Publishing Defamatory and False Content
- New Analysis Reveals the Complex Forces Driving the 'Great Human Reshuffle'
- Elevate Unveils GroundComm X30 at 2025 International GSE Expo in Las Vegas
- NEW power supply release from Kepco Dynatronix - HSP Advanced
- St. Augustine Honors Hispanic Heritage Month
- Vesica Health Receives AUA Guideline Inclusion